Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Jul 02, 2019	Grace Colón succeeds Amy Abernethy on the CareDx Board Colón brings expertise to grow patient centric innovation capabilities at CareDx BRISBANE, Calif. , July 02, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated,	View HTML
Toggle Summary Jun 27, 2019	CareDx Supports Momentum in Medicare Immunosuppressive Medication Legislation Kidney community rallies in support as introduction of the immunosuppression coverage bill is imminent BRISBANE, Calif. , June 27, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of	View HTML
Toggle Summary Jun 26, 2019	US Patent Office Issues New Transplant Patent to CareDx CareDx continues to lead innovation in transplantation BRISBANE, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic	View HTML
Toggle Summary Jun 10, 2019	CareDx to Participate in Upcoming Conferences BRISBANE, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter	View HTML
Toggle Summary May 29, 2019	CareDx Announces KidneyCare and Showcases Leadership in Transplantation at ATC CareDx leadership in transplant innovation highlighted through 12 podium and poster presentations BRISBANE, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically	View HTML
Toggle Summary May 22, 2019	CareDx to Participate in Upcoming Conferences BRISBANE, Calif. , May 22, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter	View HTML
Toggle Summary May 14, 2019	CareDx applauds HHS Report on Cost Savings of Lifetime Immunosuppressive Drug Coverage for Transplant Patients Extending Medicare coverage of medication saves $73M BRISBANE, Calif. , May 14, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions	View HTML
Toggle Summary May 08, 2019	CareDx Reports First Quarter 2019 Results AlloSure momentum drives 85% first quarter revenue growth BRISBANE, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for	View HTML
Toggle Summary May 07, 2019	CareDx’s AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019 CareDx leadership in transplant innovation highlighted through multiple podium and poster presentations BRISBANE, Calif. , May 07, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of	View HTML
Toggle Summary May 03, 2019	AlloMap In-Network with Anthem Blue Cross AlloMap now in-network for over 80% of covered lives with all US payors BRISBANE, Calif. , May 03, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic	View HTML